Novel Biomarkers of Kidney Disease in Advanced Heart Failure: Beyond GFR and Proteinuria.
Novel Biomarkers of Kidney Disease in Advanced Heart Failure: Beyond GFR and Proteinuria.
复制标题
晚期心力衰竭中肾脏疾病的新型生物标志物：超越GFR和蛋白尿。
DOI：
10.1007/s11897-022-00557-y
复制
发表时间：
2022-08
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
肾脏疾病是心力衰竭患者的常见发现，可显著影响治疗决策和结果。目前在临床实践中，使用血液中的滤过标记物来估计肾小球滤过率来确定肾功能异常，但心力衰竭背景下的肾脏疾病的表现比这复杂得多。在这篇文章中，我们回顾了新的生物标志物，这些生物标志物可能为心力衰竭患者的肾脏疾病提供更全面的评估。半乳凝素-3、ST 2、FGF-23、suPAR、miRNA、GDF-15和NAG可能是肾脏疾病进展的预后指标。L-FABP和suPAR可能有助于预测急性肾损伤（阿基）。ST 2和NAG可能在利尿剂抵抗中起作用。几种生物标志物可用于确定长期肾脏疾病进展的预后、阿基的预测和利尿剂抵抗的发展。利用这些生物标志物中的许多对心力衰竭中的肾脏疾病的机制的进一步研究可能导致治疗靶点的鉴定。
Kidney disease is a common finding in patients with heart failure and can significantly impact treatment decisions and outcomes. Abnormal kidney function is currently determined in clinical practice using filtration markers in the blood to estimate glomerular filtration rate, but the manifestations of kidney disease in the setting of heart failure are much more complex than this. In this manuscript, we review novel biomarkers that may provide a more well-rounded assessment of kidney disease in patients with heart failure. Galectin-3, ST2, FGF-23, suPAR, miRNA, GDF-15, and NAG may be prognostic of kidney disease progression. L-FABP and suPAR may help predict acute kidney injury (AKI). ST2 and NAG may be helpful in diuretic resistance. Several biomarkers may be useful in determining prognosis of long-term kidney disease progression, prediction of AKI, and development of diuretic resistance. Further research into the mechanisms of kidney disease in heart failure utilizing many of these biomarkers may lead to the identification of therapeutic targets.